Identification of structural stability and fragility of mouse liver glycogen via label-free Raman spectroscopy coupled with convolutional neural network algorithm.

Journal: International journal of biological macromolecules
PMID:

Abstract

Glycogen structure is closely associated with its physiological functions. Previous studies confirmed that liver glycogen structure had two dominant states: mainly stable during the day and largely fragile at night. However, the diurnal change of glycogen structure is impaired, with dominant fragility in diseased conditions such as diabetes mellitus and liver fibrosis. Therefore, the persistent structural fragility of glycogen particles could be a potential molecular-level pathological biomarker for early screening of certain liver diseases. However, the current method for identifying glycogen structural stability and fragility suffers from sophisticated procedures and reliance on expensive instruments, which demands developing novel methods for rapidly discriminating the two types of glycogen particles. This study applied surface-enhanced Raman spectroscopy (SERS) to generate SERS spectra of glycogen samples, revealing distinct structural differences between fragile and stable glycogen particles. Machine learning models were then constructed to predict the structural states of unknown glycogen samples via SERS spectra, according to which the convolutional neural network (CNN) model achieved the best discrimination capacity. Taken together, the SERS technique coupled with the CNN model can identify stable and fragile liver glycogen samples, facilitating the application of glycogen structural fragility as a biomarker in diagnosing liver diseases.

Authors

  • Liang Wang
    Information Department, Dazhou Central Hospital, Dazhou 635000, China.
  • Zhang-Wen Ma
    Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu Province 210000, China.
  • Jia-Wei Tang
    Department of Intelligent Medical Engineering, School of Medical Informatics and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
  • Jing-Yi Mou
    Department of Clinical Medicine, School of 1st Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu Province 210000, China.
  • Qing-Hua Liu
    State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
  • Zi-Yi Wang
    Department of Dermatology, China-Japan Friendship Hospital, Beijing 100029, China.
  • Xin Liu
    Peking University Institute of Advanced Agricultural Sciences, Shandong Laboratory of Advanced Agricultural Sciences, Weifang, Shandong, China.
  • Meng-Ying Zhang
    School of Medical Informatics and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu Province, China. Electronic address: zhangmengying@xzhmu.edu.cn.
  • Dao-Quan Tang
    Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu Province, China. Electronic address: tangdq@xzhmu.edu.cn.